Compare Repligen Corporation Common Stock (RGEN) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Spotify Technology — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while Spotify Technology trades at $520 (market cap $107.72B). The key difference: Spotify Technology is far larger — about 9.5× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Spotify Technology for 111 Days on average.
| RGEN | SPOT | |
|---|---|---|
Market Cap | $11.31B | $107.72B |
Volume | 1,216,919 | 1,447,333 |
Sector | Health | Media |
52-Week High | $194.57 | $689.21 |
52-Week Low | $102.87 | $412.75 |
Typical Hold Time | 0 Days | 111 Days |
Enterprise Value | $11.20B | $97.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Spotify (SPOT) trades at $527.45, down 0.26% with a bullish technical outlook. The company shows strong fundamental improvement with revenue growing from $11.7B in 2022 to $17.2B in 2025, while turning profitable with net income reaching $2.2B. Recent news highlights Spotify's expansion into health tech through founder Daniel Ek's Neko Health venture and new recommendation algorithm features.
The stock offers growth potential with 62% analyst buy ratings and a $588 consensus target, representing 11% upside. Key risks include recent earnings miss in Q2 2026 and competitive pressures in streaming. Positive cash flow trends and margin expansion support the bullish case, though investors should monitor Q3 2026 results due October 22.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
